-
公开(公告)号：US20240409653A1
公开(公告)日：2024-12-12
申请号：US18698354
申请日：2022-10-05
Applicant: GENMAB A/S , BIONTECH SE , MSD INTERNATIONAL BUSINESS GMBH
Inventor： Alexander MUIK , Kristina NÜRMBERGER , Nora PENCHEVA , Maria N. JURE-KUNKEL , Ugur SAHIN
Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.
-
公开(公告)号：US20240335511A1
公开(公告)日：2024-10-10
申请号：US18268124
申请日：2021-12-20
Applicant: BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Lena Mareen KRANZ , Mathias VORMEHR , Sina FELLERMEIER-KOPF , Jan DIEKMANN , David EISEL
CPC classification number: A61K38/2046 , A61K9/5146 , A61K38/2013 , A61K38/38 , A61K48/0041 , A61P35/00 , C07K14/5418 , C07K14/55 , C07K14/765 , C07K2319/31
Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer, in particular advanced solid tumors such as metastatic (Stage IV) or unresectable localized cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
-
公开(公告)号：US20210163616A1
公开(公告)日：2021-06-03
申请号：US17172694
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20240262924A1
公开(公告)日：2024-08-08
申请号：US18570257
申请日：2022-06-20
Applicant: GENMAB A/S , BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Ulf FORSSMANN , Maria N. JURE-KUNKEL , Gaurav BAJAJ , Craig THALHAUSER , Nora PENCHEVA
CPC classification number: C07K16/2878 , A61P35/00 , C07K16/2827 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31
Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.
-
公开(公告)号：US20230295335A1
公开(公告)日：2023-09-21
申请号：US18184120
申请日：2023-03-15
Applicant: Genmab A/S , BioNTech SE
Inventor： Andreea IOAN , Esther Cornelia Wilhelmina BREIJ , Lars GUELEN , David P.E. SATIJN , Ugur SAHIN , Alexander MUIK , Kristina SCHÖDEL , Sina FELLERMEIER-KOPF , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
CPC classification number: C07K16/30 , C07K16/2878 , C07K2317/31 , C07K2317/92
Abstract: The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
-
Patent Agency Ranking
公开(公告)号：US20220143144A1
公开(公告)日：2022-05-12
申请号：US17442568
申请日：2020-04-02
Applicant: BIONTECH SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Inventor： Ugur SAHIN , Mathias VORMEHR , Lena KRANZ , Sina FELLERMEIER-KOPF , Alexander MUIK , Daniel REIDENBACH , Mustafa DIKEN , Sebastian KREITER
Abstract: The present disclosure relates to methods and agents for enhancing the effect of immune effector cells, in particular immune effector cells that respond to interleukin-2 (IL2), for example effector T cells such as CD8+ T cells. Specifically, the present disclosure relates to methods comprising administering to a subject a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof and a polypeptide comprising type I interferon (IFN) or a functional variant thereof or a polynucleotide encoding a polypeptide comprising type I interferon or a functional variant thereof.
-
公开(公告)号：US20240109972A1
公开(公告)日：2024-04-04
申请号：US18038818
申请日：2021-12-07
Applicant: Genmab A/S , BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Ulf FORSSMANN , Maria JURE-KUNKEL , Manish GUPTA , Tahamtan AHMADI , Kathy AMIRI , Gaurav BAJAJ
IPC: C07K16/28 , A61K31/337 , A61K45/06 , A61P35/00
CPC classification number: C07K16/2878 , A61K31/337 , A61K45/06 , A61P35/00 , C07K16/2827 , A61K2039/505
Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.
-
公开(公告)号：US20230117803A1
公开(公告)日：2023-04-20
申请号：US17759906
申请日：2021-02-02
Applicant: BIONTECH SE
Inventor： Ugur SAHIN , Alexander MUIK , Lena KRANZ , Mathias VORMEHR
Abstract: The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising providing to the subject a peptide or protein vaccine and a binding agent, such as a bispecific antibody, binding to PD-L1 and CD137, such as human PD-L1 and human CD137, e.g., by co-administering to the subject a peptide or protein used for vaccination or a polynucleotide, in particular RNA, encoding a peptide or protein used for vaccination, and a binding agent binding to PD-L1 and CD137 or a polynucleotide, in particular RNA, encoding a binding agent binding to PD-L1 and CD137. The present disclosure further relates to medical preparations useful in the methods disclosed herein.
-
公开(公告)号：US20210277133A1
公开(公告)日：2021-09-09
申请号：US17172700
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20210269541A1
公开(公告)日：2021-09-02
申请号：US17172698
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.02 seconds)
